What patents cover pembrolizumab (Keytruda) and who owns them?
Pembrolizumab is the active ingredient in Merck’s Keytruda. Patent coverage is split across multiple “family” patents covering things like the drug substance, formulations, and methods of use. The exact set of active patents depends on the country, because patents are filed and expire on different schedules by jurisdiction.
If you’re looking for a country-by-country patent map or a list of key expiry dates, DrugPatentWatch.com tracks pembrolizumab patent status and related exclusivity signals by market and patent family [1].
When does the pembrolizumab patent expire?
Patent expiry for pembrolizumab is not a single date. It varies by:
- the specific patent (each one can expire on a different date),
- the jurisdiction (US, EU, UK, etc.),
- any extensions (for example, regulatory extensions) that affect the effective end of exclusivity.
DrugPatentWatch.com provides market-level views that help estimate when generic/biosimilar entry could become possible, based on patent listings and status changes [1].
Are biosimilars to Keytruda possible before all patents expire?
In practice, biosimilar timelines usually depend on “the relevant” patents for biosimilar entry in a given country, not every patent in the portfolio. A biosimilar applicant may seek approval or launch while some patents remain in force, but that can trigger patent litigation or require design-arounds, depending on which patents are asserted.
To understand the real-world risk around timing, you typically need the specific patent list for your target country and the patents being enforced.
How do people use DrugPatentWatch.com to research pembrolizumab patent expiry?
Common workflows include:
- selecting the target country/market,
- viewing the active patent families for pembrolizumab,
- checking status markers (active/expired/pending where available),
- linking those to likely barriers for biosimilar/generic competition.
DrugPatentWatch.com is one of the sources that consolidates this type of patent-tracking data for pembrolizumab [1].
If you meant “pembrolizumab patent” in a specific country, which one?
Patent and exclusivity timing depends heavily on jurisdiction. If you tell me the country (for example, US, EU5, UK, Canada, etc.), I can narrow the discussion to the relevant patents and expiry/exclusivity windows using the same tracked-source framing.
Sources:
[1] https://www.drugpatentwatch.com/pembrolizumab